What oral dose of torsemide or bumetanide (Bumex) is equivalent to 60 mg IV furosemide (Lasix)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Oral Conversion from 60 mg IV Furosemide

For 60 mg IV furosemide, convert to either 15 mg oral torsemide OR 1.5 mg oral bumetanide.

Conversion Ratios Based on FDA Labeling and Clinical Evidence

The FDA drug labels provide the foundational conversion ratios 1, 2:

  • Bumetanide: 1 mg bumetanide = 40 mg furosemide 2
  • Torsemide: Approximately 10 mg torsemide = 40 mg furosemide (based on initial dosing recommendations) 1

Specific Calculations for 60 mg IV Furosemide:

Bumetanide conversion:

  • 60 mg furosemide ÷ 40 = 1.5 mg bumetanide (oral)
  • Start with 1 mg twice daily or 1.5 mg once daily, maximum 10 mg/day 1

Torsemide conversion:

  • 60 mg furosemide × (10/40) = 15 mg torsemide (oral)
  • Can give as single daily dose, maximum 200 mg/day 1

Important Caveats from Recent Evidence

The 2025 TRANSFORM-Mechanism trial revealed critical findings that challenge traditional conversion ratios 3:

  • The commonly used 2:1 furosemide:torsemide ratio results in excessive natriuresis with torsemide
  • A 4:1 ratio (40 mg furosemide:10 mg torsemide) produced equivalent natriuresis
  • Higher torsemide doses caused increased neurohormonal activation (renin, aldosterone, norepinephrine) and mild kidney dysfunction 3
  • No meaningful pharmacokinetic or pharmacodynamic advantages were observed for torsemide over furosemide 3

Revised Recommendation Based on 2025 Data:

If using the 4:1 equivalence from the most recent high-quality evidence 3:

  • 60 mg IV furosemide = 15 mg oral torsemide (using 4:1 ratio: 60÷4=15)

This aligns with FDA dosing but recognize that even this may produce more diuresis than intended.

Pharmacokinetic Considerations

Torsemide advantages 4:

  • Higher bioavailability (80-90% vs 40-50% for furosemide)
  • More predictable absorption in heart failure patients
  • Longer duration of action (12-16 hours vs 6-8 hours) 5

Bumetanide advantages 6, 7:

  • Higher bioavailability (80%) compared to furosemide (40%)
  • More rapid absorption
  • Lower ototoxicity risk than furosemide 7, 8
  • 40-fold more potent than furosemide pharmacologically 7

Safety Monitoring

When converting to torsemide, monitor closely for 9:

  • Acute kidney injury (12% increased risk vs furosemide)
  • Electrolyte disturbances (potassium, sodium)
  • Volume depletion

When converting to bumetanide, monitor for 7:

  • Muscle cramps (more common than furosemide in renal disease)
  • Electrolyte abnormalities
  • Ototoxicity (lower risk than furosemide)

Clinical Algorithm

  1. Start conservative: Use 15 mg torsemide OR 1.5 mg bumetanide for 60 mg IV furosemide
  2. Assess response at 24-48 hours: Weight change, symptoms, urine output
  3. Titrate based on clinical response, not fixed ratios
  4. Monitor renal function and electrolytes within 3-7 days
  5. If inadequate response: Double the dose rather than switching agents 5

The 2022 ACC/AHA/HFSA guidelines emphasize using the lowest dose possible to maintain euvolemia and combining diuretics with guideline-directed medical therapy 5.

References

3
Research

Mechanistic Differences between Torsemide and Furosemide.

Journal of the American Society of Nephrology : JASN, 2025

6
Research

Bumetanide and furosemide.

Clinical pharmacology and therapeutics, 1983

Related Questions

In a patient with chronic heart failure who was switched from furosemide (Lasix) 20 mg to torsemide 10 mg and now has weight gain, what is the next step in management?
For a patient not responding to furosemide 60 mg daily, what initial oral torsemide dose should be started?
Can a patient be prescribed Bumex (bumetanide) in addition to furosemide?
What is the appropriate dose conversion from furosemide to torsemide for oral and intravenous administration?
What torsemide dose and dosing frequency should replace furosemide (Lasix) 20 mg twice daily in an adult with normal renal function and no contraindications to loop diuretics?
What is the differential diagnosis for a 32‑day‑old male infant recently discharged after necrotizing enterocolitis who now has two episodes of non‑bloody, non‑bilious vomiting after feeding and an abdominal radiograph showing diffusely dilated small‑bowel loops with air‑fluid levels?
What could be the cause of hemoglobin drop in a patient with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) who developed a stroke while on warfarin with an INR of 1.6?
Can high-dose oral furosemide (80 mg twice daily) cause ototoxicity?
What is the recommended management for a patient with 8/10 lumbar pain, including confirmatory medial‑branch blocks using a dual‑comparative technique and interim multimodal analgesic therapy?
What could cause persistent daytime appetite and repeated nighttime hunger episodes with normal blood glucose levels in a patient who only notices the hunger upon waking?
What are the clinical features, diagnostic criteria, and management recommendations for Prune‑1 syndrome (PRUNE1‑related neurodevelopmental disorder)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.